Bilosomal Co-Encapsulated Tamoxifen and Propranolol for Potentiated Anti-Breast Cancer Efficacy: In Vitro and In Vivo Investigation
<b>Background/Objectives</b>: Tamoxifen (TAM) is an anti-breast cancer drug suffering from acquired resistance development, prompting cancer relapse. Propranolol (PRO)’s repurposing for cancer therapy has gained interest. This work aimed to investigate combined TAM/PRO therapy for potent...
Saved in:
Main Authors: | Toka T. Elebyary, Amal A. Sultan, Sally E. Abu-Risha, Gamal M. El Maghraby, Manna Amin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-01-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/17/1/123 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Propranolol: A Promising Therapeutic Avenue for Classic Kaposi Sarcoma
by: Rasha Mahmoud Genedy, et al.
Published: (2025-01-01) -
Efficacy and safety assessment of propranolol tablets vs. oral solution for infantile hemangioma: a retrospective study in China
by: Wenting Chen, et al.
Published: (2025-02-01) -
Evaluation of Five Ready-to-Use Bases for the Topical Administration of Propranolol Hydrochloride to Treat Infantile Hemangioma
by: Chiara Lacassia, et al.
Published: (2025-01-01) -
Systematic review and meta-analysis of propranolol in the prevention and treatment of post-traumatic stress disorder
by: Haipeng Li, et al.
Published: (2025-01-01) -
LINC00626 drives tamoxifen resistance in breast cancer cells by interaction with UPF1
by: Hui Yuan, et al.
Published: (2025-01-01)